The Life Sciences team advised Moderna, Inc. (Nasdaq: MRNA) on its underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions. In addition, Moderna granted the underwriters a 30-day option to purchase up to an additional 3,947,368 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering were approximately $500 million. Goodwin also advised Moderna on its initial public offering, the largest-ever U.S. biotech IPO, in 2018.
Moderna is a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.
The Goodwin team was led by Stuart Cable, Gregg Katz, and Patty Shields.
For additional details on the offering, please read the press release.